GeneDx's (WGS) Sell (D) Rating Reaffirmed at Weiss Ratings

Key Points

• GeneDx's stock has received a "sell (d)" rating from Weiss Ratings, highlighting concerns among analysts about the company's performance.
• Despite the negative rating from Weiss, analysts show mixed sentiment; six have rated it a Buy while Zacks Research recently downgraded it from "strong-buy" to "hold".
• The stock is currently trading at $124.22, with a market cap of $3.57 billion, following a significant rise of 2.9% in its stock price.

GeneDx (NASDAQ:WGS - Get Free Report)'s stock had its "sell (d)" rating reiterated by Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

A number of other analysts also recently commented on WGS. Wall Street Zen upgraded GeneDx from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Zacks Research downgraded GeneDx from a "strong-buy" rating to a "hold" rating in a report on Thursday, October 2nd. Guggenheim restated a "buy" rating and set a $115.00 price objective (up from $88.00) on shares of GeneDx in a report on Monday, June 30th. Wells Fargo & Company upped their price target on shares of GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 30th. Finally, Piper Sandler upped their price target on shares of GeneDx from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Thursday, September 11th. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $104.13.

GeneDx Trading Up 2.9%

Shares of WGS stock traded up $3.46 on Wednesday, reaching $124.22. 275,885 shares of the stock were exchanged, compared to its average volume of 969,833. The stock has a market cap of $3.57 billion, a P/E ratio of 2,486.82 and a beta of 1.98. The company has a quick ratio of 2.70, a current ratio of 2.87 and a debt-to-equity ratio of 0.19. The firm has a 50 day moving average of $120.11 and a two-hundred day moving average of $94.73. GeneDx has a 1-year low of $51.04 and a 1-year high of $136.00.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.40. The business had revenue of $102.69 million during the quarter, compared to the consensus estimate of $86.00 million. GeneDx had a return on equity of 16.51% and a net margin of 0.39%. GeneDx has set its FY 2025 guidance at EPS. On average, research analysts anticipate that GeneDx will post 0.97 EPS for the current year.

Insider Transactions at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 3,728 shares of the firm's stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $121.47, for a total value of $452,840.16. Following the transaction, the chief financial officer owned 8,755 shares of the company's stock, valued at $1,063,469.85. This trade represents a 29.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Katherine Stueland sold 10,501 shares of the firm's stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total transaction of $1,275,556.47. Following the completion of the transaction, the chief executive officer directly owned 14,578 shares in the company, valued at $1,770,789.66. This represents a 41.87% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 556,371 shares of company stock valued at $67,489,314. Company insiders own 29.60% of the company's stock.

Institutional Investors Weigh In On GeneDx

Hedge funds have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. acquired a new position in shares of GeneDx during the first quarter valued at approximately $44,614,000. William Blair Investment Management LLC increased its stake in shares of GeneDx by 37.2% during the second quarter. William Blair Investment Management LLC now owns 1,631,402 shares of the company's stock valued at $150,595,000 after acquiring an additional 442,414 shares during the period. Alliancebernstein L.P. increased its stake in shares of GeneDx by 3,054.5% during the first quarter. Alliancebernstein L.P. now owns 436,900 shares of the company's stock valued at $38,694,000 after acquiring an additional 423,050 shares during the period. Jennison Associates LLC increased its stake in shares of GeneDx by 6,163.1% during the second quarter. Jennison Associates LLC now owns 397,896 shares of the company's stock valued at $36,730,000 after acquiring an additional 391,543 shares during the period. Finally, Westfield Capital Management Co. LP increased its stake in shares of GeneDx by 164.8% during the second quarter. Westfield Capital Management Co. LP now owns 589,188 shares of the company's stock valued at $54,388,000 after acquiring an additional 366,711 shares during the period. Institutional investors own 61.72% of the company's stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.